Vaccitech plc Stock News

相关临床试验将评估把免疫疗法VTP-300与NA疗法联合使用的RNAi疗法AB-729 相关临床试验将评估把免疫疗法VTP-300与NA疗法联合使用的RNAi疗法AB-729

試驗將評估 AB-729，是結合了 VTP-300、一種免疫療法以及 NA 療法的一種 RNAi 療法 試驗將評估 AB-729，是結合了 VTP-300、一種免疫療法以及 NA 療法的一種 RNAi

RNAi 신약 후보인 AB-729와 면역치료제인 VTP-300, NA 치료요법의 복합 형태 평가 RNAi 신약 후보인 AB-729와 면역치료제인 VTP-300, NA 치료요법의 복합 형태 평가

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics a

OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of th

Revenue Sharing Arrangement with University of Oxford Could Deliver Further Payments to Vaccitech Arising from Milestones and Royalties Revenue Sharing Arrangement with University of Oxford Could Deli

Vaccitech (NASDAQ: VACC) is known to be the spin-off from Oxford University behind AstraZeneca Sars-Cov-2 vaccine.

OXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of th

OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics

MOSCOW , Feb. 14, 2022 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia''s sovereign wealth fund), R-Pharm group and AstraZeneca announce interim results of phase II clinical trials to evaluate the safety and immunogenicity of the combined use of AstraZeneca''s vaccine and the first component of the Sputnik V coronavirus vaccine (Sputnik Lite). According to the interim results of the trials, involving 100 volunteers in Russia and 100 volunteers in Azerbaijan , the vaccines combination demonstrated an acceptable safety profile, which is consistent with the results of previous AstraZeneca vaccine, Sputnik V and Sputnik Lite vaccines clinical trials. Volunteers were being monitored for 57 days after the first dose. Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered. The research conducted by RDIF, the Gamaleya Center, AstraZeneca, and R-Pharm is the first study in the world to evaluate the combined use of components of different adenovirus vaccines to prevent coronavirus infection.

Cancer Research UK, Vaccitech (VACC) and the Ludwig Institute for Cancer Research said the first patient was dosed in a phase 1/2a trial called MAGE trial evaluating

OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dos

Vaccitech plc - ADR (VACC) shares closed today 12.3% lower than it did at the end of yesterday. The stock is currently down 10.4% year-to-date, down 29.4% over the past 12 months, and down 29.4% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $11.90 and as low as $9.23 this week.Shares closed 44.7% below its 52-week high and 32.7% above its 52-week low.Trading volume this week was 94.5% lower than the 10-day average and 92.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 11.0% lower than its 5-day moving average, 5.9% lower than its 20-day moving average, and 23.6% lower than its 90-day moving average. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 4243.5% The company's stock price performance over the past 12 months lags the peer average by 85.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc ("Vaccitech"), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader ("KOL") event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics landscape. The event will be webcast live on January 25 th at 8:30 a.m. EST. Featured speakers: Dr. Kaushik Agarwal, consultant hepatologist and transplant physician at the Institute of Liver Studies at King''s College Hospital, Viral Hepatitis Service lead, and Director of the NIHR South London Clinical Research Network. Dr. Henry L. Y. Chan, head of the Division of Gastroenterology and Hepatology, Director of the Institute of Digestive Disease, the Center for Liver Health, and the Office of Global Engagement. Dr. Chan is also the Assistant Dean of External Affairs for the Faculty of Medicine at CUHK and the Course Director for the Master of Science in Gastroenterology at CUHK.